Coferon Dimers for Intracellular Protein Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug design approaches fail to effectively target intracellular protein-protein interactions or signaling, as antibodies are too large to enter cells, while small molecule drugs lack the specificity to bind to extended protein surfaces.
Innovation Solution
Development of therapeutic coferon dimers, comprising a phenylboronic acid linker element and a 1,2 diol binding partner linker element, which form specific binding interactions with intracellular protein targets, allowing for tight and specific binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody therapeutics are used to target protein-protein interactions, then binding specificity is improved, but molecular size increases preventing cellular penetration
Solution Approach 1:
The antibody is segmented into smaller fragments (Fab, scFv, diabodies) that retain binding specificity while reducing molecular size to enable cellular penetration. The patent describes generating library members that are antibody fragments rather than full-length antibodies, allowing them to bind specific epitopes while being small enough to enter cells.
Solution Approach 2:
The patent uses combinatorial library generation to add diversity in the binding region while maintaining a constrained framework structure. This dimensional approach allows optimization of binding specificity through variable CDR regions while the framework provides structural stability and appropriate size for cellular penetration.
2Weight of moving object
If small molecule drugs are used to reduce molecular size for cellular penetration, then cell entry is improved, but binding specificity to extended protein surfaces deteriorates
Solution Approach 1:
The antibody fragments are composed of framework regions providing structural stability and CDR regions providing binding specificity. This composite structure combines the advantages of large molecules (specificity) with the advantages of small molecules (cellular penetration), creating a hybrid therapeutic agent.
Solution Approach 2:
The patent applies local quality by having the CDR regions provide high binding specificity to target epitopes while the framework regions provide structural support and maintain appropriate molecular size. Different regions of the antibody fragment have specialized functions that together resolve the contradiction between size and specificity.
3Reliability
If combinatorial libraries are generated to improve binding diversity, then binding affinity is improved, but library complexity and screening difficulty increase
Solution Approach 1:
The patent employs phage display technology to create a dynamic library system where binding events are amplified through biological replication. High-affinity binders are enriched through iterative selection rounds, allowing the library to dynamically evolve toward higher binding affinity while managing complexity through biological selection rather than exhaustive screening.
Solution Approach 2:
The selection process incorporates feedback mechanisms where binding results from one round inform the selection strategy for subsequent rounds. High-affinity binders are identified and used to guide further library construction and selection, creating a feedback loop that systematically improves binding affinity while managing library complexity through informed iterative optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The coferon dimers achieve high affinity binding to protein targets, enabling modulation of protein-protein interactions and signaling with increased specificity and reduced toxicity, and can be orally active and penetrate tumors.
Implementation Method 1
the phenylboronic acid linker element binds to the 1,2 diol binding partner linker element to form a boronate ester
Implementation Method 2
the first diversity element binds to the target, and (3) the second diversity element binds to the target
Data Source
Figure 1
Figure 2.1A~2.1K
Figure 2.2L~2.2S
AI summary
A monomer useful in prepaπng therapeutic compounds includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 11 M and a linker element connected to the diversity element The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or noncovalent interaction with a binding partner of the linker element The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof